Inovio Pharmaceuticals (INO) Prostate Cancer Vaccine Shows Success in Primate Trial
Inovio Pharmaceuticals Inc., a leading developer of therapeutic and preventive vaccines, today announced that its SynCon ™ therapeutic DNA vaccine (INO-5150) for prostate cancer demonstrated positive immune responses in monkeys. The company said the results support similarly strong, antigen-specific and sustainable T cell levels in previously reported data from earlier animal studies. Inovio said the new data reinforces its plan to a start phase I clinical trial for INO-5150 by the middle of next year. Dr. J. Joseph Kim, Ph.D., president & CEO of Inovio, emphasized the potential of the vaccine in human models. "The immune response data achieved by…